Health TrialsbyHealthPanel

A Hospital-Based Registry of Preventive Cardiology Clinics

ConditionsCardiovascular MorbidityCardiovascular Risk AssesmentPrimary Prevention CVD
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18-90
SponsorNational Institute of Cardiovascular Diseases, Pakistan

About this trial

More research is needed to articulate the most effective ways to use these tools as screening tests in cardiovascular risk assessments and how they ultimately affect CVD mortality and morbidity outcomes. Clinicians are encouraged to continue sharing decision-making with patients to combine their unique cardiovascular risk factors and develop a comprehensive, effective treatment plan.

Eligibility criteria

This trial accepts healthy volunteers

Qualifiers

All individuals attending the preventive cardiology clinics.

Disqualifiers

• Individuals who refused to give consent.

Trial population

Both genders, age 18 and above, visiting preventive cardiology clinics with or without established CVD and may or may not have CVD risk factors.

Trial design

Design model

Cohort

Time perspective

Prospective

Treatments tested in this trial

  • Cardiovascular risk assesment

    Other intervention

    ASCVD Score and WHO Cardiovascular Risk score.

Treatment groups

10,000 Participants
are divided into 1 treatment group
Group A: Adult patients1 intervention

Trial outcomes

Primary outcomes

1

cardiovascular risk assesesment

risk stratification of Cardiovascular diseases (CVD) in patients without established CVD but with CVD co morbids.we are using Atherosclerotic Cardiovascular Diseases (ASCVD) Risk Score and World Heart Organization(WHO) Risk Score for CVD Risk Assesment. In ASCVD Risk Score, we categorize population into low risk ( score \<5), borderline(score between 5 and 7.4) ,intermediate( score between 7.5 an 19.9) and high risk (score\>20), using all parameters for risk assesment. For WHO risk score calculation we are using WHO Risk score system for South Asia. https://cdn.who.int/media/docs/default-source/cardiovascular-diseases/south-asia.pdf?sfvrsn=c5b0d9a3\_2

Time frame
Ten years

Secondary outcomes

1

Cardiovascular risk reduction

CVD risk reduction in patients with or without established CVD but with CVD co morbids.

Time frame
Ten years
2

Cardiovascular related deaths

Estimation of patients who expired in their follow up despite CVD risk factors management.

Time frame
Ten years.

Other outcomes

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

National Institute of Cardiovascular Diseases, Pakistan

Lead sponsor

Source ClinicalTrials.gov
Apply now